Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEP) Short Interest Up 110.9% in February

Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEP) saw a large growth in short interest in the month of February. As of February 28th, there was short interest totalling 29,100 shares, a growth of 110.9% from the February 13th total of 13,800 shares. Based on an average daily volume of 374,100 shares, the days-to-cover ratio is currently 0.1 days. Currently, 1.1% of the shares of the company are sold short.

Coeptis Therapeutics Price Performance

Shares of NASDAQ COEP opened at $11.06 on Friday. The company has a current ratio of 0.40, a quick ratio of 0.40 and a debt-to-equity ratio of 0.03. The stock has a fifty day simple moving average of $10.59 and a two-hundred day simple moving average of $6.21. Coeptis Therapeutics has a 1-year low of $2.31 and a 1-year high of $13.70. The firm has a market cap of $35.86 million, a price-to-earnings ratio of -1.91 and a beta of -0.77.

Coeptis Therapeutics Company Profile

Coeptis Therapeutics Holdings, Inc, a biopharmaceutical company, develops cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological malignancies and solid tumors; and CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy.